| Common Variable Immunodeficiency
Asceniv vs Hizentra
Side-by-side clinical, coverage, and cost comparison for common variable immunodeficiency.Deep comparison between: Asceniv vs Hizentra with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHizentra has a higher rate of injection site reactions vs Asceniv based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Hizentra but not Asceniv, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Asceniv
Hizentra
At A Glance
IV infusion
Every 3-4 weeks
IgG replacement therapy
SC injection
Daily to every 2 weeks
Immune globulin
Indications
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Primary immune deficiency disorder
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Wiskott-Aldrich Syndrome
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Severe Combined Immunodeficiency
Dosing
Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300 to 800 mg/kg IV every 3 to 4 weeks; start infusion at 0.5 mg/kg/min for the first 15 minutes and increase gradually up to 8 mg/kg/min if tolerated.
Primary immune deficiency disorder, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Severe Combined Immunodeficiency Individualized SC dose administered daily to every 2 weeks; when switching from IGIV, initial weekly dose = prior IGIV dose (g) divided by weeks between doses, multiplied by 1.37.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 0.2 g/kg (1 mL/kg) SC per week in 1-2 infusion sessions over 1-2 consecutive days; may increase to 0.4 g/kg per week if symptoms worsen on the lower dose.
Contraindications
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies to IgA and history of hypersensitivity
- History of anaphylactic or severe systemic reaction to human immune globulin or inactive ingredients of HIZENTRA, including polysorbate 80
- Hyperprolinemia Type I or II (HIZENTRA contains L-proline as stabilizer)
- IgA-deficiency with antibodies against IgA and a history of hypersensitivity
Adverse Reactions
Most common (>=5%) Headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, nausea
Postmarketing Apnea, ARDS, cyanosis, dyspnea, bronchospasm, cardiac arrest, vascular collapse, hypotension, coma, loss of consciousness, seizures, tremor, Stevens-Johnson syndrome, epidermolysis, erythema multiforme, bullous dermatitis, pancytopenia, leukopenia, pyrexia, rigors, hepatic dysfunction, abdominal pain
Most common (>=5%) Local infusion-site reactions (swelling, redness, heat, pain, hematoma, itching), headache, diarrhea, fatigue, back pain, nausea, pain in extremity, cough, upper respiratory tract infection, rash, pruritus, vomiting, abdominal pain, migraine, arthralgia, pain, fall, nasopharyngitis
Postmarketing Allergic-anaphylactic reactions (swollen face or tongue, pharyngeal edema, pyrexia, chills, dizziness, hypertension, malaise, tachycardia, flushing), chest discomfort, dyspnea, tremor, burning sensation, infusion site ulcer, infusion site necrosis
Pharmacology
ASCENIV is an intravenous immunoglobulin replacement therapy that provides a broad spectrum of neutralizing IgG antibodies against bacterial and viral pathogens and their toxins; IgG antibodies act as opsonins to increase phagocytosis and elimination of pathogens from the circulation.
Immune Globulin Subcutaneous (Human), 20% Liquid that supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents; mechanism of action has not been fully elucidated but may include immunomodulatory effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Asceniv
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Hizentra
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Asceniv
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Hizentra
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Asceniv
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Hizentra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$75/fillfill
ADvantage Ig Patient Support Program: AscenivCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Hizentra.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AscenivView full Asceniv profile
HizentraView full Hizentra profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.